119 results
Page 3 of 6
6-K
EX-99.1
ipoejp4qqyb9zs
8 Mar 22
Current report (foreign)
8:49am
6-K
EX-1.1
740qagr lvjis
11 Feb 22
Current report (foreign)
5:29pm
424B5
jox1grcasymz6
11 Feb 22
Prospectus supplement for primary offering
5:28pm
6-K
41cjrogf5x b0uiamus
20 Dec 21
Current report (foreign)
7:54am
6-K
EX-99.1
hn6lhqe
20 Dec 21
Current report (foreign)
7:54am
6-K
EX-99.2
se9pmzjwm
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.3
kn1kjx
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
yfhx s1njx687rjk
15 Nov 21
VBL Therapeutics Reports Third Quarter 2021 Financial Results
7:00am
6-K
EX-99.1
603kv tlhr7kmllk
5 Oct 21
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
4:17pm
6-K
EX-99.1
bkmduo4eff9295 w51
17 Sep 21
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to
7:36am
6-K
EX-99.2
nwdiehdy5j gknkj
2 Sep 21
Notice of Annual General Meeting of Shareholders
7:20am
6-K
EX-99.1
bg8ay
30 Aug 21
Current report (foreign)
7:50am
6-K
id1dvq81opjb257v8r9
16 Aug 21
Current report (foreign)
7:00am
6-K
EX-99.1
h7xwgfr
8 Jul 21
VBL Therapeutics Appoints Alison Finger and Michael Rice to its Board of Directors
4:05pm
6-K
EX-99.1
bgxu7d hnus4
15 Jun 21
VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
7:51am
6-K
EX-99.1
pju8gmp814ijdtqv
4 Jun 21
Current report (foreign)
8:05am
6-K
rodbk95pw7tusiv
11 May 21
Current report (foreign)
7:00am
POS AM
vo8ni
19 Apr 21
Prospectus update (post-effective amendment)
5:17pm
424B8
zeqii8ii
19 Apr 21
Prospectus unintentially filed late
5:06pm